The HMG20A Knockout HT29 Polyclonal Cells from Ascent Research constitute a CRISPR/Cas9-mediated gene-disruption pool derived from the HT29 human colorectal adenocarcinoma cell line. This product is provided as a polyclonal population, meaning it comprises a mixture of cells harboring diverse editing events at the HMG20A locus, thereby abrogating gene function without clonal isolation or characterization of individual alleles. The polyclonal format offers a robust and representative loss-of-function model, minimizing clonal artifacts while facilitating high-throughput studies. Researchers can employ these cells to interrogate the role of HMG20A in chromatin organization, transcriptional repression, and colorectal cancer pathophysiology.
HT29 cells are a widely employed model of human colorectal adenocarcinoma, originally established from a primary tumor of a 44-year-old female Caucasian patient. These adherent epithelial cells display characteristics of intestinal epithelium and are known for their tumorigenic properties, including constitutive activation of Wnt signaling and mutations in APC, TP53, and KRAS. The HT29 line serves as a valuable substrate for investigating colorectal cancer biology, drug responses, and gene function in a disease-relevant context. Culturing these knockout cells under standard conditions maintains the parental line’s adherent growth and epithelial morphology, ensuring compatibility with established experimental protocols.
HMG20A (iBRAF) is a transcriptional co-repressor and a core component of the LSD1-CoREST (BHC) histone demethylase complex. This complex includes KDM1A (LSD1), RCOR1 (CoREST), HDAC1, HDAC2, and HMG20B, and it removes methyl groups from histone H3 lysine 4 (H3K4), thereby repressing transcription. HMG20A directly interacts with KDM1A and RCOR1 and is recruited to chromatin by the transcription factor REST to silence neuronal genes like SCN1A and SYN1 in non-neuronal tissues. Through these interactions, HMG20A plays a critical role in maintaining cell-type-specific gene expression programs, influencing neurogenesis and differentiation. In colorectal cancer, HMG20A may modulate chromatin states at genes involved in proliferation and epithelial identity.
Disruption of HMG20A in HT29 colorectal cancer cells destabilizes the LSD1-CoREST complex, leading to altered histone methylation and derepression of target genes. This can affect REST-dependent neuronal genes and other loci involved in cell cycle control and differentiation. The resulting phenotypic changes may include altered proliferation, migration, and drug sensitivity. As an epigenetic modulator, HMG20A knockout provides a system to study chromatin-based gene regulation in a colorectal cancer model, enabling identification of HMG20A-dependent pathways relevant to tumor biology.
These knockout cells support a wide array of experimental approaches. Chromatin analysis via ChIP-qPCR can assess histone modification changes, while transcriptomic profiling by RNA-seq and RT-qPCR reveals gene expression alterations. Protein detection through Western blotting and immunofluorescence, along with functional assays for migration, invasion, and chemosensitivity, enables comprehensive characterization. This model is thus ideal for epigenetic drug target validation and colorectal cancer studies. For more information, contact Ascent Research.
